GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bomedemstat tosylate overview

IMG-7289 is under development for the treatment of acute myelogenous leukemia (AML), polycythemia vera, essential thrombocythemia, myelodysplastic syndrome (MDS), myelofibrosis including post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), primary myelofibrosis and new chemical entities for hemoglobinopathies (hemoglobin deficiencies) and solid tumors (other malignances). It is administered through oral route. The drug candidate acts by targeting lysine specific demethylase 1 (LSD-1 or KDM1A).

Imago BioSciences overview

Imago BioSciences is a clinical-stage pharmaceutical company. The company developed lysine-specific demethylase 1(LSD1) inhibitors which help to regulate the growth of bone marrow cells. It develops drugs for acute myeloid leukemia, proliferative diseases, myelofibrosis, polycythemia vera, myelodysplastic syndrome, and essential thrombocythemia. The company is funded by Clarus Ventures, Frazier Healthcare Partners, Amgen Ventures, and Merck Research Laboratories Ventures Fund. It has an operational presence across San Francisco, Boston, and the UK. Imago BioSciences is headquartered in San Francisco, California, the US.

For a complete picture of Bomedemstat tosylate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.